









市场行情
/
股票
/
nasdaq-jazz
/

Jazz Pharmaceuticals PLC

JAZZ

166.990USD

+0.990+0.60%

收盘 12/19, 16:00（美东）报价延迟15分钟

10.14B总市值

亏损市盈率 TTM



Jazz Pharmaceuticals PLC

166.990

+0.990+0.60%

概览公司财务分析

概览

公司

财务

分析

关于 Jazz Pharmaceuticals PLC 公司

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Jazz Pharmaceuticals PLC简介



公司代码JAZZ

公司名称Jazz Pharmaceuticals PLC

上市日期Jan 18, 2012

CEOGala (Renee D)

员工数量2800

证券类型Ordinary Share

年结日Jan 18

公司地址Fifth Floor, Waterloo Exchange

城市DUBLIN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Ireland

邮编- -

电话35316347800

网址https://www.jazzpharma.com/

公司代码JAZZ

上市日期Jan 18, 2012

CEOGala (Renee D)

Jazz Pharmaceuticals PLC公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

292.32K

-5.03%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.12K

-0.17%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

24.12K

-22.89%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

Dr. Norbert G. Riedel, Ph.D.

Independent Director

13.92K

+13.93%

Ms. Anne O'Riordan

Independent Director

12.77K

+15.38%

Ms. Samantha Pearce

Executive Vice President, Chief Commercial Officer

9.24K

-5.88%

Ms. Jennifer E. Cook

Independent Director

7.11K

+31.50%

名称

名称/职务

职务

持股

持股变动

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.28%

Mr. Bruce C. Cozadd

Chairman of the Board

292.32K

-5.03%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

48.12K

-0.17%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

24.12K

-22.89%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Xywav

415.32M

39.72%

Epidiolex/epidyolex

251.73M

24.07%

Rylaze

100.66M

9.63%

Zepzelca

74.54M

7.13%

High-sodium oxybate AG royalty revenue

54.14M

5.18%

其他

149.32M

14.28%

地区USD

名称

营收

占比

United States

936.28M

89.54%

Europe

82.76M

7.91%

All Others

26.67M

2.55%

业务

地区

业务USD

名称

营收

占比

Xywav

415.32M

39.72%

Epidiolex/epidyolex

251.73M

24.07%

Rylaze

100.66M

9.63%

Zepzelca

74.54M

7.13%

High-sodium oxybate AG royalty revenue

54.14M

5.18%

其他

149.32M

14.28%

股东统计

更新时间: 12月4日周四

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.68%

BlackRock Institutional Trust Company, N.A.

8.25%

Dimensional Fund Advisors, L.P.

4.67%

Capital World Investors

4.20%

LSV Asset Management

4.13%

其他

69.06%

持股股东

占比

The Vanguard Group, Inc.

9.68%

BlackRock Institutional Trust Company, N.A.

8.25%

Dimensional Fund Advisors, L.P.

4.67%

Capital World Investors

4.20%

LSV Asset Management

4.13%

其他

69.06%

股东类型

持股股东

占比

Investment Advisor

50.91%

Investment Advisor/Hedge Fund

34.93%

Hedge Fund

10.56%

Research Firm

3.49%

Individual Investor

3.02%

Pension Fund

1.77%

Venture Capital

1.30%

Bank and Trust

0.85%

Sovereign Wealth Fund

0.09%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

1197

64.03M

105.38%

-5.21M

2025Q2

1199

63.76M

105.11%

-6.47M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

2023Q2

1197

61.00M

95.34%

-4.11M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

6.07M

10%

+73.43K

+1.22%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.22M

8.61%

+11.23K

+0.22%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

2.54M

4.18%

+209.41K

+8.99%

Jun 30, 2025

Capital World Investors

2.54M

4.19%

+616.73K

+31.99%

Jun 30, 2025

LSV Asset Management

2.55M

4.21%

+87.58K

+3.55%

Jun 30, 2025

State Street Investment Management (US)

1.94M

3.19%

-31.20K

-1.59%

Jun 30, 2025

EcoR1 Capital, LLC

1.71M

2.81%

Jun 30, 2025

JP Morgan Asset Management

1.55M

2.55%

+46.92K

+3.12%

Jun 30, 2025

Fuller & Thaler Asset Management Inc.

1.63M

2.69%

+297.95K

+22.39%

Jun 30, 2025

Columbia Threadneedle Investments (US)

1.54M

2.54%

+186.67K

+13.80%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Cambria Cannabis ETF

4.08%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

3.11%

iShares U.S. Pharmaceuticals ETF

3.08%

Invesco Pharmaceuticals ETF

2.94%

State Street SPDR S&P Pharmaceuticals ETF

2.83%

Abacus FCF International Leaders ETF

2.69%

First Trust NASDAQ Pharmaceuticals ETF

2.51%

Clough Hedged Equity ETF

2.4%

Alger Russell Innovation ETF

2.12%

VictoryShares Small Cap Free Cash Flow ETF

1.77%

Cambria Cannabis ETF

占比4.08%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比3.11%

iShares U.S. Pharmaceuticals ETF

占比3.08%

Invesco Pharmaceuticals ETF

占比2.94%

State Street SPDR S&P Pharmaceuticals ETF

占比2.83%

Abacus FCF International Leaders ETF

占比2.69%

First Trust NASDAQ Pharmaceuticals ETF

占比2.51%

Clough Hedged Equity ETF

占比2.4%

Alger Russell Innovation ETF

占比2.12%

VictoryShares Small Cap Free Cash Flow ETF

占比1.77%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Jazz Pharmaceuticals PLC的前五大股东是谁？



Jazz Pharmaceuticals PLC 的前五大股东如下：
The Vanguard Group, Inc.持有股份：6.07M，占总股份比例：10.00%。
BlackRock Institutional Trust Company, N.A.持有股份：5.22M，占总股份比例：8.61%。
Dimensional Fund Advisors, L.P.持有股份：2.54M，占总股份比例：4.18%。
Capital World Investors持有股份：2.54M，占总股份比例：4.19%。
LSV Asset Management持有股份：2.55M，占总股份比例：4.21%。